IP Library › Granted Patent US 11,786,454
Granted Patent B2
US 11,786,454 · App. 15/056,239 · Granted Oct 17, 2023

Compositions for topical treatment of microbial infections

Inventor: Patrick M. Schlievert (Iowa City, IA)
Assignee: Hennepin Life Sciences, LLC
A61K9/0014A61K9/06A61K31/04A61K31/195A61K31/23A61K45/06A61K47/10A61K47/14A61K47/38A61K47/44Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,786,454
App. No.
15/056,239
Granted
Oct 17, 2023
Kind
B2
Abstract

The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Claims (14)

1. A method of treating or preventing a gram-positive bacterial skin infection, a gram-positive bacterial infection of a wound, or a gram-positive bacterial infection of surgical incision cite in a subject in need thereof, the method comprising the step of topically administering an effective amount of a composition comprising

GML and a non-aqueous gel comprised of a combination of propylene glycol, polyethylene glycol, and cellulose derivative and the non-aqueous gel having a pH from about 4.0 to about 4.5, wherein the non-aqueous gel is at a concentration of about 10% to about 25% of the composition,

to treat or prevent the gram-positive bacterial skin infection, the gram-positive bacterial infection of a wound, or the gram-positive bacterial infection of surgical incision cite in the subject,

wherein GML is present at a concentration of about 10 μg/mL to about 100 mg/mL; and

wherein the GML is the isomer of GML with lauric acid in the 2-position of glycerol.

2. The method of 1 , wherein the non-aqueous composition further comprises a pharmaceutically acceptable topical carrier.

3. The method of 1 , wherein the non-aqueous composition further comprises an accelerant selected from an organic acid, a chelator, an antibiotic agent, an anti-fungal agent, an anti-viral agent, or a combination thereof.

4. The method of 1 , wherein GML comprises about 0.001% (w/v) to about 10% (w/v) of the composition.

5. The method of 1 , further comprising administering a second active agent selected from an antibiotic, an anti-fungal agent, or an anti-viral agent.

6. The method of claim 1 , wherein the gram-positive bacterial infection is a Staphylococcus infection.

7. The method of claim 1 wherein the gram-positive bacterial infection is methicillin-resistant Staphylococcus aureus.

8. The method of 1 , wherein the gram-positive bacterial infection is a Streptococcus infection.

9. The method of 1 , wherein the subject is a human.

10. The method of 1 , the method further comprising using a sponge, wipe, or swab to topically apply the non-aqueous composition.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR EXECUTION DATE AND ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 059406 FRAME: 0580. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Mar 31, 2022
From: SCHLIEVERT, PATRICK M.
To: HENNEPIN LIFE SCIENCES, LLC
Reel/Frame 059556/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2022
From: SCHLIEVERT, PATRICK M.
To: HENNIPEN LIFE SCIENCES, LLC
Reel/Frame 059406/0580 →
Continuity (4)
Division 13866722 · Apr 19, 2013
Provisional Application 61636203 · Apr 20, 2012
Provisional Application 61650755 · May 23, 2012
Related Publication 20160175244A1 · Jun 23, 2016